CJC-1295 (no DAC) + Ipamorelin 10mg

This vial holds two compounds at 5 mg each, acting on different receptors. Those separate receptors are why the pairing exists.

CJC-1295 without DAC is also called Modified GRF 1-29. It reproduces the first 29 residues of growth hormone releasing hormone, the minimal sequence that still gives full GHRH receptor activity, and carries four substitutions with four separate purposes. D-Ala at position 2 blocks dipeptidyl peptidase-4, the main route by which native GHRH is cleaved. Gln at 8 replaces an asparagine prone to deamidation. Ala at 15 raises intrinsic potency at the receptor. Leu at 27 replaces a methionine open to oxidation. Together they extend functional plasma half-life roughly fourfold over native GHRH, to around 30 minutes. The DAC version adds an albumin-binding linker and lasts days; this one does not, which keeps release pulsatile.

Ipamorelin is a pentapeptide, Aib-His-D-2-Nal-D-Phe-Lys-NH2, and an agonist at GHS-R1a, the ghrelin receptor. Its distinguishing feature is what it does not do: in the original characterisation it released growth hormone with potency comparable to GHRP-6 while leaving ACTH and cortisol at baseline, at doses reported up to 200 times the GH-releasing dose. GHRP-6 and GHRP-2 both raise them.

Both act at the pituitary. IGF-1 LR3 sits downstream of this axis and is the usual choice for studying the output rather than the trigger.

Supplied as a lyophilised powder at ≥99% purity by HPLC, with batch LC-MS identity confirmation and a certificate of analysis. Reconstitute with bacteriostatic water. Store the sealed vial at -20°C and keep reconstituted solution at 2-8°C, protected from light.

For in-vitro laboratory research only. Not for human or veterinary use.